AMD 3465 is a potent, selective CXCR4 antagonist and exhibits 8-fold higher affinity than AMD 3100 and inhibits SDF-1α-ligand binding (Ki = 41.7 nM).

BKT140 is a CXCR4 antagonist with an IC50 value of ~1 nM.

LIT-927 is a neutraligand of CXCL12 (Ki= 267 nM) with anti-inflammatory effect and it has a high binding selectivity for CXCL12 over other chemokines

JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM.

AMD-070 is a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay, and inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs.

MSX-122 is a small molecule and partial CXCR4 antagonist, with potent inhibition of CXCR4/CXCL12 actions (IC50 = 10 nM).

AMD-070 HCl is a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay and inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs.

AMD 3465 hexahydrobromide is a potent, selective CXCR4 antagonist and exhibits 8-fold higher affinity than AMD 3100 and inhibits SDF-1α-ligand binding (Ki = 41.7 nM).

LY2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration, LY2510924 binds to the chemokine receptor CXCR4, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation.

USL311 is a selective CXCR4 antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4[1].

Decursin is a cumarin isolated from Radix peucedani that exhibits a number of physiological actions including anticancer, antibacterial, antinematodal and antioxidant. It inhibited proliferation and angiogenesis of endothelial cells to suppress diabetic retinopathy via VEGFR2.

AZD 5069 is a selective and reversible antagonist of CXCR2 that can inhibit CXCL8 binding to CXCR2 with pIC50 of 9.1.

AZD8797 is an allosteric non-competitive and orally active modulator of the human CX3CR1 receptor which antagonizes CX3CR1 and CXCR2 with Kis of 3.9 and 2800 nM, respectively.

SB-265610 is a potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca2+ mobilization (IC50 values are 3.4 and 6800 nM respectively). It inhibits CINC-induced chemotaxis and attenuates neutrophil accumulation in inflammatory lung injury in vivo.

ZK756326 is a full agonist of CCR8（Chemokine receptor 8） with an IC50 of 1.8 μM, dose-responsively eliciting an increase in intracellular calcium and cross-desensitizing the response of the receptor to CCL1.

NBI-74330 is a small molecule antagonist for CXCR3, NBI-74330 demonstrates potent inhibition of [(125)I]CXCL10 and [(125)I]CXCL11 specific binding (K (i) of 1.5 and 3.2 nM, respectively.

SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity.